-
公开(公告)号：US08075878B2
公开(公告)日：2011-12-13
申请号：US11812361
申请日：2007-06-18
Applicant: William A. Carter , David Strayer
Inventor： William A. Carter , David Strayer
CPC classification number: A61K38/212
Abstract: An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human α-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.
-
2.发明申请GENETEC REGULATION OF HOST DEFENSE MECHANISMS BY MUCOSAL EXPOSURE TO NATURAL INTERFERON ALPHA SPECIES 审中-公开通过自然暴露于自然干扰物种的遗传机制对遗传机制的监测公开(公告)号：US20110044946A1
公开(公告)日：2011-02-24
申请号：US12735753
申请日：2009-02-17
Applicant: William A. Carter , David Strayer
Inventor： William A. Carter , David Strayer
CPC classification number: A61K38/212 , A61K9/0014
Abstract: A mixture of α-interferons (IFN-α) is used in vitro or in vivo as an antimicrobial agent or anticancer agent. It may be administered by topical application to oral or nasal, and/or buccal mucosa to combat the effects of infection by bacteria or protozoa, cancer, or other pathogenic disease process (e.g., autoimmune or neurodegenerative disease).
Abstract translation: α-干扰素（IFN-α）的混合物在体外或体内用作抗微生物剂或抗癌剂。 它可以通过局部施用给口服或鼻腔和/或颊粘膜来对抗细菌或原生动物，癌症或其它致病性疾病过程（例如自身免疫性或神经变性疾病）感染的作用。
-
公开(公告)号：US07693697B2
公开(公告)日：2010-04-06
申请号：US10269422
申请日：2002-10-11
Applicant: Dwayne Westenskow , James Agutter , Noah Syroid , David Strayer , Robert Albert , Frank Drews
Inventor： Dwayne Westenskow , James Agutter , Noah Syroid , David Strayer , Robert Albert , Frank Drews
CPC classification number: G06F19/3456 , A61B5/00 , G06F19/00 , G06F19/3481 , G06T11/206 , G16H50/50
Abstract: A method, system and apparatus for the monitoring, diagnosis and evaluation of the state of a dynamic drug display system is disclosed. This invention provides for the rapid cognitive grasp of the overall state of drug combination effects with respect to a dynamic system. The system provides for displayed objects, which change in real-time to show the changes of the functions of the system. In particular, this invention is directed to the processing and display of drug data for the use of doctors in the process of monitoring or administering drugs to patients.
Abstract translation: 公开了用于动态药物显示系统的状态的监视，诊断和评估的方法，系统和装置。 本发明提供了关于动态系统的药物组合效应的总体状态的快速认知掌握。 系统提供显示对象，实时更改以显示系统功能的更改。 特别地，本发明涉及在向患者监测或给予药物的过程中使用医生的药物数据的处理和显示。
-
4.发明授权公开(公告)号：US07654966B2
公开(公告)日：2010-02-02
申请号：US10269423
申请日：2002-10-11
Applicant: Dwayne Westinskow , James Agutter , Noah Syroid , David Strayer , Robert Albert , S. Blake Wachter , Frank Drews
Inventor： Dwayne Westinskow , James Agutter , Noah Syroid , David Strayer , Robert Albert , S. Blake Wachter , Frank Drews
IPC: A61B5/08
CPC classification number: A61B5/00 , A61B5/0205 , A61B5/742
Abstract: A method, system, apparatus and device for the monitoring, diagnosis and evaluation of the state of a dynamic pulmonary system is disclosed. This method and system provides the processing means for receiving sensed and/or simulated data, converting such data into a displayable object format and displaying such objects in a manner such that the interrelationships between the respective variables can be correlated and identified by a user. This invention provides for the rapid cognitive grasp of the overall state of a pulmonary critical function with respect to a dynamic system.
Abstract translation: 公开了一种用于监测，诊断和评估动态肺动脉系统状态的方法，系统，装置和装置。 该方法和系统提供了用于接收感测和/或模拟数据的处理装置，将这些数据转换成可显示对象格式，并以这样一种方式显示这些对象，使得各个变量之间的相互关系可以由用户相关和识别。 本发明提供了关于动态系统的肺部关键功能的总体状态的快速认知掌握。
-
公开(公告)号：US20090304630A1
公开(公告)日：2009-12-10
申请号：US11882532
申请日：2007-08-02
Applicant: William A. Carter , David Strayer
Inventor： William A. Carter , David Strayer
IPC: A61K38/21 , A61K31/7052 , A61P11/00
CPC classification number: A61K31/4196 , A61K31/24 , A61K31/7088 , A61K38/005 , A61K38/212 , A61K48/00 , A61K2300/00 , C12N15/111 , C12N15/117 , C12N2310/17 , C12N2320/31
Abstract: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA. Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase influenza virus inhibitor. These two products, dsRNA, and alpha interferon, have therapeutic utility either given preventively (prophylactically) or in treatment of active disease. These unique immunological/antiviral actions, operating through immunological “cascades” ameliorates the lethal effects of viral mutation which, by causing resistance to commonly available drugs, greatly accelerates the death rate. For example, in 1918-1920, Avian Influenza caused the death of approximately 40 million people worldwide (ref. National Geographic, September, 2005).
Abstract translation: 用天然人α干扰素，dsRNA或天然人α干扰素和dsRNA治疗严重急性呼吸综合征。 用天然人α干扰素，神经氨酸酶抑制剂和利巴韦林治疗禽流感。 使用dsRNA与神经氨酸酶流感病毒抑制剂组合，可以缓解流感病毒的影响。 这两种产品，dsRNA和α干扰素具有预防性（预防性）或治疗活动性疾病的治疗效用。 通过免疫学“级联”操作的这些独特的免疫/抗病毒作用改善了病毒突变的致死作用，通过引起对常用药物的抗性，极大地加速了死亡率。 例如，在1918年至1920年间，禽流感导致全世界约4000万人死亡（参考国家地理杂志，2005年9月）。
-
Patent Agency Ranking
公开(公告)号：US20070224219A1
公开(公告)日：2007-09-27
申请号：US11634389
申请日：2006-12-06
Applicant: William Carter , David Strayer
Inventor： William Carter , David Strayer
IPC: A61K39/145 , A61K48/00
CPC classification number: A61K39/145 , A61K39/12 , A61K39/39 , A61K2039/5252 , A61K2039/543 , A61K2039/545 , A61K2039/55511 , A61K2039/55561 , A61K2039/58 , C12N2760/16134
Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.
Abstract translation: 通过作为佐剂或免疫兴奋剂，dsRNA与抗流感疫苗一起使用来促进针对急性或慢性病毒感染的疫苗保护。
-
公开(公告)号：US20060035859A1
公开(公告)日：2006-02-16
申请号：US11244107
申请日：2005-10-06
Applicant: William Carter , David Strayer
Inventor： William Carter , David Strayer
CPC classification number: A61K31/4196 , A61K31/24 , A61K31/7088 , A61K38/005 , A61K38/212 , A61K48/00 , A61K2300/00 , C12N15/111 , C12N15/117 , C12N2310/17 , C12N2320/31
Abstract: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA. Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase influenza virus inhibitor. These two products, dsRNA, and alpha interferon, have therapeutic utility either given preventively (prophylactically) or in treatment of active disease. These unique immunological/antiviral actions, operating through immunological “cascades” ameliorates the lethal effects of viral mutation which, by causing resistance to commonly available drugs, greatly accelerates the death rate. For example, in 1918-1920, Avian Influenza caused the death of approximately 40 million people worldwide (ref. National Geographic, September 2005).
Abstract translation: 用天然人α干扰素，dsRNA或天然人α干扰素和dsRNA治疗严重急性呼吸综合征。 用天然人α干扰素，神经氨酸酶抑制剂和利巴韦林治疗禽流感。 使用dsRNA与神经氨酸酶流感病毒抑制剂组合，可以缓解流感病毒的影响。 这两种产品，dsRNA和α干扰素具有预防性（预防性）或治疗活动性疾病的治疗效用。 通过免疫学“级联”操作的这些独特的免疫/抗病毒作用改善了病毒突变的致死作用，通过引起对常用药物的抗性，极大地加速了死亡率。 例如，在1918年至1920年间，禽流感导致全球约4000万人死亡（参考国家地理杂志，2005年9月）。
-
公开(公告)号：US20100310600A1
公开(公告)日：2010-12-09
申请号：US12735755
申请日：2009-02-17
Applicant: William A. Carter , David Strayer
Inventor： William A. Carter , David Strayer
IPC: A61K31/7105 , A61K39/12 , A61K39/02 , A61K39/00 , A61K39/002 , A61P35/04 , A61P33/00 , A61P31/04 , A61P31/12
CPC classification number: A61K31/7105 , Y02A50/409 , Y02A50/411 , Y02A50/478
Abstract: A mismatched double-stranded ribonucleic acid, which is an agonist for Toll-like receptor 3 (TLR3), is used in vitro or in vivo as an antimicrobial agent, antiproliferative agent, and/or immunostimulant. Poly(l:C11-14U) is a more selective agonist of TLR3 as compared to poly(l:C) even though the both double-stranded RNA are structurally analogous.
Abstract translation: 作为Toll样受体3（TLR3）的激动剂的错配的双链核糖核酸在体外或体内用作抗微生物剂，抗增殖剂和/或免疫刺激剂。 尽管两个双链RNA在结构上类似，但Poly（I：C11-14U）是与poly（1：C）相比更有选择性的TLR3激动剂。
-
9.发明申请公开(公告)号：US20080019943A1
公开(公告)日：2008-01-24
申请号：US11812361
申请日：2007-06-18
Applicant: William Carter , David Strayer
Inventor： William Carter , David Strayer
CPC classification number: A61K38/212
Abstract: An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human α-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.
Abstract translation: 通过口服给予人α-干扰素的感染动物（包括人）诱导动物中的抗病毒/免疫调节反应。 描述赋予抗性或减轻暴露于禽流感病毒的影响的方法。
-
公开(公告)号：US20120004290A1
公开(公告)日：2012-01-05
申请号：US13256039
申请日：2010-03-10
Applicant: David Strayer , William A. Carter
Inventor： David Strayer , William A. Carter
IPC: A61K31/713 , A61P43/00 , C07H21/02
CPC classification number: A61K31/713
Abstract: Chronic fatigue syndrome and prolonged QT interval are treated using one or more different double-stranded ribonucleic acids (dsRNA).
Abstract translation: 使用一种或多种不同的双链核糖核酸（dsRNA）治疗慢性疲劳综合征和延长的QT间期。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.021 seconds)
